Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 8/20 | 0.65 |
| ▸ | HRH1 | P35367 | 12/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 10/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 10/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | HRH2 | P25021 | 2/20 | 0.38 |
| ▸ | HTR2B | P41595 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23908928 | 0.90 | S1PR2 (0.63) | S1PR2HRH1ADRA1AADRA1BKCNH2 | |
| SCHEMBL23966878 | 0.83 | S1PR2 (0.56) | S1PR2HRH1ADRA1AADRA1BKCNH2 | |
| SCHEMBL23908998 | 0.80 | S1PR2 (0.83) | S1PR2 | |
| SCHEMBL23908887 | 0.78 | S1PR2 (0.94) | S1PR2 | |
| SCHEMBL23909089 | 0.78 | S1PR2 (0.78) | S1PR2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL23908861 | 0.76 | S1PR2 (0.76) | S1PR2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL23966578 | 0.75 | S1PR2 (0.44) | S1PR2HRH1ADRA1AADRA1BKCNH2 | |
| SCHEMBL23908732 | 0.73 | S1PR2 (0.71) | S1PR2 | |
| SCHEMBL23908830 | 0.73 | S1PR2 (1.00) | S1PR2KCNH2 | |
| SCHEMBL23914820 | 0.71 | S1PR2 (0.94) | S1PR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3649119-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GALAPAGOS NV (BE) | 2021-11-03 | — | — | EP | disclosed |